MedTrace Logo

Menorrhagia Study in Women With Treatment-resistant Menorrhagia

NCT00288691 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2014-12-30

No results posted yet for this study

Summary

The aim of this study is to explore effects of the investigational product for the treatment of treatment-resistant menorrhagia without organic cause.

Conditions

  • Menorrhagia

Interventions

DRUG

Asoprisnil (BAY86-5294)

5mg/day

DRUG

Asoprisnil (BAY86-5294)

10mg/day

DRUG

Asoprisnil (BAY86-5294)

25mg/day

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • TAP Pharmaceutical Products Inc.

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-30
Completion
2004-01-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00288691 on ClinicalTrials.gov